Hot News: Goldcorp Inc. (NYSE:GG), Northern Oil and Gas, Inc. (NYSEMKT:NOG), Silicom Ltd. (NASDAQ:SILC), JinkoSolar Holding (NYSE:JKS), Celldex Therapeutics (NASDAQ:CLDX)

Goldcorp Inc. (NYSE:GG) belongs to Basic Materials sector. Its net profit margin is -66.00% and weekly performance is 1.61%. On last trading day company shares ended up $16.44. Goldcorp Inc. (NYSE:GG) distance from 50-day simple moving average (SMA50) is -6.43%. Goldcorp Inc. (NYSE:GG) announced that it has extended the deadline for former shareholders of Probe Mines (“Probe”) to file tax election forms to August 31, 2015.

Northern Oil and Gas, Inc. (NYSEMKT:NOG) shares fell -4.43% in last trading session and ended the day at $5.82. NOG Gross Margin is 90.10% and its return on assets is -4.00%. Northern Oil and Gas, Inc. (NYSEMKT:NOG) quarterly performance is -32.72%. National Securities began coverage on shares of Northern Oil and Gas, Inc. (NYSEMKT:NOG) in a report released on Thursday. The firm issued a buy rating and a $7.00 price objective on the energy company’s stock.

On 10 July, Silicom Ltd. (NASDAQ:SILC) shares moved up 1.92% and was closed at $26.57. SILC EPS growth in last 5 year was 25.44%. Silicom Ltd. (NASDAQ:SILC) year to date (YTD) performance is -20.69%. On 8 July, Silicom Ltd. (NASDAQ:SILC) announced a Design Win with a rapidly-growing provider of high-performance storage solutions whose related orders are projected to ramp up to approximately $1 million per year.

On 10 July, JinkoSolar Holding Co., Ltd. (NYSE:JKS) shares moved up 3.64% and was closed at $25.34. JKS EPS growth in last 5 year was 51.60%. JinkoSolar Holding Co., Ltd. (NYSE:JKS) year to date (YTD) performance is 28.56%.JinkoSolar Holding Co., Ltd. (NYSE:JKS) said that, it is scheduled to next report earnings for the current quarter on 2015-08-17.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved up 1.72% in last trading session and ended the day at $24.89. CLDX return on assets is -48.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -12.85%.On 1 July, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the promotion of Richard Wright, Ph.D. to Senior Vice President and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex’s cancer immunotherapy pipeline.

Leave a Reply

Your email address will not be published. Required fields are marked *